$MDT
Medtronic plc

2020 Q2 Form 10-K Financial Statement

#000161310320000021 Filed on June 19, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2020 Q1 2019 Q4
Revenue $5.998B $7.717B $7.706B
YoY Change -26.37% 2.27% 3.01%
Cost Of Revenue $2.232B $2.400B $2.394B
YoY Change -8.9% 5.96% 8.67%
Gross Profit $3.734B $5.317B $5.312B
YoY Change -34.06% 0.68% 0.64%
Gross Profit Margin 62.25% 68.9% 68.93%
Selling, General & Admin $2.310B $2.587B $2.620B
YoY Change -12.5% -0.35% 0.58%
% of Gross Profit 61.86% 48.66% 49.32%
Research & Development $568.0M $573.0M $603.0M
YoY Change -4.38% 2.14% 2.2%
% of Gross Profit 15.21% 10.78% 11.35%
Depreciation & Amortization $672.0M $663.0M $671.0M
YoY Change 0.75% -1.78% 3.07%
% of Gross Profit 18.0% 12.47% 12.63%
Operating Expenses $3.307B $3.160B $3.223B
YoY Change -5.19% 0.1% 0.88%
Operating Profit $427.0M $1.639B $1.351B
YoY Change -80.37% 6.29% -12.5%
Interest Expense -$16.00M $156.0M $165.0M
YoY Change -83.84% -35.8% -31.54%
% of Operating Profit -3.75% 9.52% 12.21%
Other Income/Expense, Net -$11.00M $96.00M $108.0M
YoY Change -35.29% 35.21% 107.69%
Pretax Income $205.0M $1.579B $1.294B
YoY Change -84.13% 15.26% -4.5%
Income Tax -$401.0M -$340.0M -$77.00M
% Of Pretax Income -195.61% -21.53% -5.95%
Net Earnings $646.0M $1.915B $1.364B
YoY Change -44.88% 50.91% 22.33%
Net Earnings / Revenue 10.77% 24.82% 17.7%
Basic Earnings Per Share $0.48 $1.43 $1.02
Diluted Earnings Per Share $0.48 $1.42 $1.01
COMMON SHARES
Basic Shares Outstanding 1.341B shares 1.341B shares 1.341B shares
Diluted Shares Outstanding 1.352B shares 1.351B shares

Balance Sheet

Concept 2020 Q2 2020 Q1 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.95B $11.63B $10.40B
YoY Change 11.17% 27.19% 2.62%
Cash & Equivalents $4.140B $3.709B $3.962B
Short-Term Investments $6.808B $7.919B $6.436B
Other Short-Term Assets $2.209B $2.045B $2.095B
YoY Change 3.03% 1.49% 4.02%
Inventory $4.229B $4.122B $4.042B
Prepaid Expenses
Receivables $4.645B $6.248B $6.118B
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $22.03B $24.04B $22.65B
YoY Change 0.29% 15.17% 4.62%
LONG-TERM ASSETS
Property, Plant & Equipment $4.828B $4.764B $4.756B
YoY Change 3.27% 3.72% 4.85%
Goodwill $39.84B $40.09B $39.95B
YoY Change -0.3% 0.22% 3.49%
Intangibles $19.06B $19.46B $19.78B
YoY Change -7.28% -6.62% -5.01%
Long-Term Investments $480.0M $480.0M $432.0M
YoY Change 29.03% 45.45% -15.46%
Other Assets $2.094B $2.196B $2.113B
YoY Change 106.51% 137.15% 88.16%
Total Long-Term Assets $68.66B $68.78B $68.40B
YoY Change 1.37% 1.36% 2.86%
TOTAL ASSETS
Total Short-Term Assets $22.03B $24.04B $22.65B
Total Long-Term Assets $68.66B $68.78B $68.40B
Total Assets $90.69B $92.82B $91.05B
YoY Change 1.11% 4.61% 3.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.996B $1.945B $1.965B
YoY Change 2.2% 14.01% 12.8%
Accrued Expenses $4.839B $5.256B $4.672B
YoY Change -0.94% 9.59% 1.43%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.776B $844.0M $875.0M
YoY Change 231.26% -37.76% -34.85%
Total Short-Term Liabilities $10.37B $8.735B $8.170B
YoY Change 22.36% -1.33% -3.46%
LONG-TERM LIABILITIES
Long-Term Debt $22.14B $24.73B $24.75B
YoY Change -9.82% 4.47% 4.56%
Other Long-Term Liabilities $1.664B $1.784B $1.758B
YoY Change 119.82% 148.12% 142.82%
Total Long-Term Liabilities $23.80B $1.784B $1.758B
YoY Change -5.95% 148.12% 142.82%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.37B $8.735B $8.170B
Total Long-Term Liabilities $23.80B $1.784B $1.758B
Total Liabilities $39.82B $40.87B $40.33B
YoY Change 0.85% 5.36% 4.94%
SHAREHOLDERS EQUITY
Retained Earnings $28.13B $28.21B $27.02B
YoY Change 7.09% 9.47% 7.34%
Common Stock $0.00 $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $50.74B $51.81B $50.58B
YoY Change
Total Liabilities & Shareholders Equity $90.69B $92.82B $91.05B
YoY Change 1.11% 4.61% 3.29%

Cashflow Statement

Concept 2020 Q2 2020 Q1 2019 Q4
OPERATING ACTIVITIES
Net Income $646.0M $1.915B $1.364B
YoY Change -44.88% 50.91% 22.33%
Depreciation, Depletion And Amortization $672.0M $663.0M $671.0M
YoY Change 0.75% -1.78% 3.07%
Cash From Operating Activities $1.450B $2.407B $1.867B
YoY Change -30.52% 17.13% 60.53%
INVESTING ACTIVITIES
Capital Expenditures -$336.0M -$293.0M -$283.0M
YoY Change 0.3% -2.98% 37.38%
Acquisitions
YoY Change
Other Investing Activities $701.0M -$1.508B -$933.0M
YoY Change -461.34% 113.3% -385.32%
Cash From Investing Activities $365.0M -$1.801B -$1.216B
YoY Change -169.0% 78.49% -1104.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.310B -873.0M -1.741B
YoY Change 52.33% -31.15% 0.64%
NET CHANGE
Cash From Operating Activities 1.450B 2.407B 1.867B
Cash From Investing Activities 365.0M -1.801B -1.216B
Cash From Financing Activities -1.310B -873.0M -1.741B
Net Change In Cash 505.0M -267.0M -1.090B
YoY Change -27.65% 20.27% 144.39%
FREE CASH FLOW
Cash From Operating Activities $1.450B $2.407B $1.867B
Capital Expenditures -$336.0M -$293.0M -$283.0M
Free Cash Flow $1.786B $2.700B $2.150B
YoY Change -26.26% 14.55% 57.05%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 dei Entity Registrant Name
EntityRegistrantName
Medtronic plc
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0001613103
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--04-24
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
D02 XH02
CY2020 mdt Defined Contribution Plan Treasury Bond Rate Of Guaranteed Rate Of Return
DefinedContributionPlanTreasuryBondRateOfGuaranteedRateOfReturn
P10Y
CY2020Q2 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:OtherAssets
CY2020Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesCurrent
CY2020Q2 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesNoncurrent
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-04-24
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020 dei City Area Code
CityAreaCode
1
CY2020 dei Local Phone Number
LocalPhoneNumber
438-1700
CY2020 dei Entity File Number
EntityFileNumber
1-36820
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
L2
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1183488
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
20 On Hatch, Lower Hatch Street
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
Dublin 2
CY2020 dei Entity Address Country
EntityAddressCountry
IE
CY2020 dei Country Region
CountryRegion
353
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2020 dei Entity Small Business
EntitySmallBusiness
false
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2019Q4 dei Entity Public Float
EntityPublicFloat
141300000000 USD
CY2020Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1341298882 shares
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
28913000000 USD
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
30557000000 USD
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
29953000000 USD
CY2020 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
9424000000 USD
CY2019 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
9155000000 USD
CY2018 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
9067000000 USD
CY2020 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2331000000 USD
CY2019 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2330000000 USD
CY2018 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2256000000 USD
CY2020 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
10109000000 USD
CY2019 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
10418000000 USD
CY2018 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
10238000000 USD
CY2020 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1756000000 USD
CY2019 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1764000000 USD
CY2018 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1823000000 USD
CY2020 mdt Restructuring Charges Netof Restructuring Reversals
RestructuringChargesNetofRestructuringReversals
118000000 USD
CY2019 mdt Restructuring Charges Netof Restructuring Reversals
RestructuringChargesNetofRestructuringReversals
198000000 USD
CY2018 mdt Restructuring Charges Netof Restructuring Reversals
RestructuringChargesNetofRestructuringReversals
30000000 USD
CY2020 us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
313000000 USD
CY2019 us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
166000000 USD
CY2018 us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
61000000 USD
CY2020 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
0 USD
CY2019 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
0 USD
CY2018 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
697000000 USD
CY2020 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-71000000 USD
CY2019 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-258000000 USD
CY2018 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-535000000 USD
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
4791000000 USD
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
6268000000 USD
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
6640000000 USD
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
356000000 USD
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
373000000 USD
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
181000000 USD
CY2020 us-gaap Interest Expense
InterestExpense
1092000000 USD
CY2019 us-gaap Interest Expense
InterestExpense
1444000000 USD
CY2018 us-gaap Interest Expense
InterestExpense
1146000000 USD
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
4055000000 USD
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
5197000000 USD
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
5675000000 USD
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-751000000 USD
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
547000000 USD
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2580000000 USD
CY2020 us-gaap Profit Loss
ProfitLoss
4806000000 USD
CY2019 us-gaap Profit Loss
ProfitLoss
4650000000 USD
CY2020 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
17000000 USD
CY2018 us-gaap Profit Loss
ProfitLoss
3095000000 USD
CY2019 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
19000000 USD
CY2018 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-9000000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
4789000000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
4631000000 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
3104000000 USD
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.57
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.44
CY2018 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.29
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.54
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.41
CY2018 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.27
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1340700000 shares
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1346400000 shares
CY2018 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1356700000 shares
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1351100000 shares
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1357500000 shares
CY2018 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1368200000 shares
CY2020 us-gaap Profit Loss
ProfitLoss
4806000000 USD
CY2019 us-gaap Profit Loss
ProfitLoss
4650000000 USD
CY2018 us-gaap Profit Loss
ProfitLoss
3095000000 USD
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
45000000 USD
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
102000000 USD
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-103000000 USD
CY2020 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-829000000 USD
CY2019 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-1375000000 USD
CY2018 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
1184000000 USD
CY2020 mdt Other Comprehensive Income Loss Unrealized Gain Loss On Derivatives Arising During Period Net Investment Hedge Net Of Tax
OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax
405000000 USD
CY2019 mdt Other Comprehensive Income Loss Unrealized Gain Loss On Derivatives Arising During Period Net Investment Hedge Net Of Tax
OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax
88000000 USD
CY2018 mdt Other Comprehensive Income Loss Unrealized Gain Loss On Derivatives Arising During Period Net Investment Hedge Net Of Tax
OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax
0 USD
CY2020 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
544000000 USD
CY2019 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
191000000 USD
CY2018 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
-167000000 USD
CY2020 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
72000000 USD
CY2019 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
401000000 USD
CY2018 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
-218000000 USD
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-851000000 USD
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-975000000 USD
CY2018 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1030000000 USD
CY2020 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
3955000000 USD
CY2019 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
3675000000 USD
CY2018 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
4125000000 USD
CY2020 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
15000000 USD
CY2019 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
16000000 USD
CY2018 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-9000000 USD
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
3940000000 USD
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
3659000000 USD
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
4134000000 USD
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4140000000 USD
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4393000000 USD
CY2020Q2 us-gaap Short Term Investments
ShortTermInvestments
6808000000 USD
CY2019Q2 us-gaap Short Term Investments
ShortTermInvestments
5455000000 USD
CY2020Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
208000000 USD
CY2019Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
190000000 USD
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4645000000 USD
CY2019Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6222000000 USD
CY2020Q2 us-gaap Inventory Net
InventoryNet
4229000000 USD
CY2019Q2 us-gaap Inventory Net
InventoryNet
3753000000 USD
CY2020Q2 us-gaap Other Assets Current
OtherAssetsCurrent
2209000000 USD
CY2019Q2 us-gaap Other Assets Current
OtherAssetsCurrent
2144000000 USD
CY2020Q2 us-gaap Assets Current
AssetsCurrent
22031000000 USD
CY2019Q2 us-gaap Assets Current
AssetsCurrent
21967000000 USD
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4828000000 USD
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4675000000 USD
CY2020Q2 us-gaap Goodwill
Goodwill
39841000000 USD
CY2019Q2 us-gaap Goodwill
Goodwill
39959000000 USD
CY2020Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
19063000000 USD
CY2019Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
20560000000 USD
CY2020Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
2832000000 USD
CY2019Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
1519000000 USD
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2094000000 USD
CY2019Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1014000000 USD
CY2020Q2 us-gaap Assets
Assets
90689000000 USD
CY2019Q2 us-gaap Assets
Assets
89694000000 USD
CY2020Q2 us-gaap Debt Current
DebtCurrent
2776000000 USD
CY2019Q2 us-gaap Debt Current
DebtCurrent
838000000 USD
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1996000000 USD
CY2019Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1953000000 USD
CY2020Q2 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
2099000000 USD
CY2019Q2 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
2189000000 USD
CY2020Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
502000000 USD
CY2019Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
567000000 USD
CY2020Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2993000000 USD
CY2019Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2925000000 USD
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
10366000000 USD
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
8472000000 USD
CY2020Q2 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
22021000000 USD
CY2019Q2 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
24486000000 USD
CY2020Q2 us-gaap Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
1910000000 USD
CY2019Q2 us-gaap Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
1651000000 USD
CY2020Q2 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
2682000000 USD
CY2019Q2 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
2838000000 USD
CY2020Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1174000000 USD
CY2019Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1278000000 USD
CY2020Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1664000000 USD
CY2019Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
757000000 USD
CY2020Q2 us-gaap Liabilities
Liabilities
39817000000 USD
CY2019Q2 us-gaap Liabilities
Liabilities
39482000000 USD
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2600000000 shares
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2600000000 shares
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1341074724 shares
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1341074724 shares
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1340697595 shares
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1340697595 shares
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
0 USD
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
0 USD
CY2020Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
26165000000 USD
CY2019Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
26532000000 USD
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
28132000000 USD
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
26270000000 USD
CY2020Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3560000000 USD
CY2019Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2711000000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
50737000000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
50091000000 USD
CY2020Q2 us-gaap Minority Interest
MinorityInterest
135000000 USD
CY2019Q2 us-gaap Minority Interest
MinorityInterest
121000000 USD
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
50872000000 USD
CY2019Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
50212000000 USD
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
90689000000 USD
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
89694000000 USD
CY2017Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
50330000000 USD
CY2018 us-gaap Profit Loss
ProfitLoss
3095000000 USD
CY2018 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1030000000 USD
CY2018 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.84
CY2018 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
2494000000 USD
CY2018 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
329000000 USD
CY2018 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
2097000000 USD
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
344000000 USD
CY2018 us-gaap Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
-11000000 USD
CY2018Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
50822000000 USD
CY2019 us-gaap Profit Loss
ProfitLoss
4650000000 USD
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-975000000 USD
CY2019 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
2.00
CY2019 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
2693000000 USD
CY2019 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
923000000 USD
CY2019 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
2808000000 USD
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
290000000 USD
CY2019 us-gaap Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
3000000 USD
CY2019Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
50212000000 USD
CY2020 us-gaap Profit Loss
ProfitLoss
4806000000 USD
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-851000000 USD
CY2020 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
2.16
CY2020 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
2894000000 USD
CY2020 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
564000000 USD
CY2020 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
1228000000 USD
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
297000000 USD
CY2020 us-gaap Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
-1000000 USD
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
50872000000 USD
CY2020 us-gaap Profit Loss
ProfitLoss
4806000000 USD
CY2019 us-gaap Profit Loss
ProfitLoss
4650000000 USD
CY2018 us-gaap Profit Loss
ProfitLoss
3095000000 USD
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2663000000 USD
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2659000000 USD
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2644000000 USD
CY2020 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
99000000 USD
CY2019 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-457000000 USD
CY2019 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
78000000 USD
CY2018 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
52000000 USD
CY2020 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-1315000000 USD
CY2019 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-304000000 USD
CY2018 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-919000000 USD
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
297000000 USD
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
290000000 USD
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
344000000 USD
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-406000000 USD
CY2018 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-38000000 USD
CY2020 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
0 USD
CY2019 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
0 USD
CY2018 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
697000000 USD
CY2020 us-gaap Impairment Of Investments
ImpairmentOfInvestments
0 USD
CY2019 us-gaap Impairment Of Investments
ImpairmentOfInvestments
0 USD
CY2018 us-gaap Impairment Of Investments
ImpairmentOfInvestments
227000000 USD
CY2020 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-217000000 USD
CY2019 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-257000000 USD
CY2018 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-73000000 USD
CY2020 us-gaap Increase Decrease In Accounts And Notes Receivable
IncreaseDecreaseInAccountsAndNotesReceivable
-1291000000 USD
CY2019 us-gaap Increase Decrease In Accounts And Notes Receivable
IncreaseDecreaseInAccountsAndNotesReceivable
581000000 USD
CY2018 us-gaap Increase Decrease In Accounts And Notes Receivable
IncreaseDecreaseInAccountsAndNotesReceivable
275000000 USD
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
577000000 USD
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
274000000 USD
CY2018 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
192000000 USD
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-44000000 USD
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
399000000 USD
CY2018 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
65000000 USD
CY2020 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
609000000 USD
CY2019 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
624000000 USD
CY2018 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-229000000 USD
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
7007000000 USD
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
7234000000 USD
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
4684000000 USD
CY2020 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
488000000 USD
CY2019 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
1827000000 USD
CY2018 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
137000000 USD
CY2020 us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
0 USD
CY2019 us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
0 USD
CY2018 us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
6058000000 USD
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1213000000 USD
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1134000000 USD
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1068000000 USD
CY2020 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
11039000000 USD
CY2019 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
2532000000 USD
CY2018 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
3200000000 USD
CY2020 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
9574000000 USD
CY2019 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
4683000000 USD
CY2018 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
4227000000 USD
CY2020 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
37000000 USD
CY2019 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-36000000 USD
CY2018 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
22000000 USD
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3203000000 USD
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-774000000 USD
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5858000000 USD
CY2020 us-gaap Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less
ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess
-17000000 USD
CY2019 us-gaap Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less
ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess
-713000000 USD
CY2018 us-gaap Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less
ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess
-249000000 USD
CY2020 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
5568000000 USD
CY2019 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
7794000000 USD
CY2018 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
21000000 USD
CY2020 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
6110000000 USD
CY2019 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
7948000000 USD
CY2019 us-gaap Interest Paid Net
InterestPaidNet
973000000 USD
CY2018 us-gaap Interest Paid Net
InterestPaidNet
1147000000 USD
CY2018 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
7370000000 USD
CY2020 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
2894000000 USD
CY2019 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
2693000000 USD
CY2018 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
2494000000 USD
CY2020 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
662000000 USD
CY2019 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
992000000 USD
CY2018 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
403000000 USD
CY2020 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1326000000 USD
CY2019 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2877000000 USD
CY2018 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2171000000 USD
CY2020 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-81000000 USD
CY2019 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
14000000 USD
CY2018 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-94000000 USD
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-4198000000 USD
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-5431000000 USD
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-11954000000 USD
CY2020 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year.
CY2020 us-gaap Use Of Estimates
UseOfEstimates
The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States (U.S.) (U.S. GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Estimates are used when accounting for items such as income taxes, contingencies, intangible asset, and liability valuations. Actual results may or may not differ from those estimates.
CY2020 us-gaap Fiscal Period
FiscalPeriod
The Company utilizes a 52/53-week fiscal year, ending the last Friday in April, for the presentation of its consolidated financial statements and related notes thereto at April 24, 2020 and April 26, 2019 and for each of the three fiscal years ended April 24, 2020 (fiscal year 2020), April 26, 2019 (fiscal year 2019), and April 27, 2018 (fiscal year 2018). Fiscal years 2020, 2019, 2018 were 52-week years. The Company's fiscal year 2021 is a 53-week year, with the extra week occurring during the first quarter, and will end on April 30, 2021.
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-86000000 USD
CY2019 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-78000000 USD
CY2018 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
114000000 USD
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-253000000 USD
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
724000000 USD
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1298000000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4393000000 USD
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3669000000 USD
CY2017Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4967000000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4140000000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4393000000 USD
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3669000000 USD
CY2020 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
878000000 USD
CY2019 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1558000000 USD
CY2018 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2542000000 USD
CY2020 us-gaap Interest Paid Net
InterestPaidNet
643000000 USD
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
30557000000 USD
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
29953000000 USD
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
28913000000 USD
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
28913000000 USD
CY2019Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
315000000 USD
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
30557000000 USD
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
29953000000 USD
CY2020Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
303000000 USD
CY2020 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
220000000 USD
CY2020Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
1100000000 USD
CY2020 us-gaap Revenue Performance Obligation Description Of Timing
RevenuePerformanceObligationDescriptionOfTiming
four years
CY2020Q2 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
280000000 USD
CY2019Q2 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
222000000 USD
CY2019Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
5540000000 USD
CY2019Q2 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
222000000 USD
CY2018Q2 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
173000000 USD
CY2020 mdt Business Acquisition Purchase Price Contingent Consideration
BusinessAcquisitionPurchasePriceContingentConsideration
125000000 USD
CY2019 mdt Business Acquisition Purchase Price Contingent Consideration
BusinessAcquisitionPurchasePriceContingentConsideration
151000000 USD
CY2020 mdt Business Acquisition Contingent Consideration Milestone Payment
BusinessAcquisitionContingentConsiderationMilestonePayment
34000000 USD
CY2019 mdt Business Acquisition Contingent Consideration Milestone Payment
BusinessAcquisitionContingentConsiderationMilestonePayment
36000000 USD
CY2020 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
33000000 USD
CY2019 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
66000000 USD
CY2020Q2 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
280000000 USD
CY2019Q2 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
222000000 USD
CY2018 mdt Restructuring Charges Netof Accrual Adjustments
RestructuringChargesNetofAccrualAdjustments
107000000 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
6847000000 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
135000000 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
141000000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
6841000000 USD
CY2019 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Reductions Securities Sold
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsReductionsSecuritiesSold
0 USD
CY2019Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
20000000 USD
CY2019Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
61000000 USD
CY2019Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
5499000000 USD
CY2020Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
1453000000 USD
CY2020Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
6000000 USD
CY2020Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
4019000000 USD
CY2020Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
135000000 USD
CY2019Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
1075000000 USD
CY2019Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
9000000 USD
CY2019Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
2181000000 USD
CY2019Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
52000000 USD
CY2020 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
9559000000 USD
CY2019 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
3718000000 USD
CY2018 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
3309000000 USD
CY2020 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
25000000 USD
CY2019 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
18000000 USD
CY2018 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
27000000 USD
CY2020 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
22000000 USD
CY2019 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
62000000 USD
CY2018 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
21000000 USD
CY2019Q2 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0 USD
CY2020Q2 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0 USD
CY2020 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Reductions Securities Sold
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsReductionsSecuritiesSold
0 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
2190000000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
2854000000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
1733000000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Maturities After Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
64000000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
6841000000 USD
CY2020 us-gaap Impairment Of Investments
ImpairmentOfInvestments
0 USD
CY2019 us-gaap Impairment Of Investments
ImpairmentOfInvestments
0 USD
CY2018 us-gaap Impairment Of Investments
ImpairmentOfInvestments
227000000 USD
CY2018Q2 mdt Costand Equity Method Investments Carrying Value Before Realized Loss
CostandEquityMethodInvestmentsCarryingValueBeforeRealizedLoss
317000000 USD
CY2020Q2 us-gaap Debt Current
DebtCurrent
2776000000 USD
CY2019Q2 us-gaap Debt Current
DebtCurrent
838000000 USD
CY2020Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
5000000 USD
CY2019Q2 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
6000000 USD
CY2020Q2 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
15000000 USD
CY2019Q2 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
-29000000 USD
CY2020Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
45000000 USD
CY2020Q2 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0.0893
CY2019Q2 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
10000000 USD
CY2019Q2 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0.0639
CY2020Q2 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
104000000 USD
CY2019Q2 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
104000000 USD
CY2020Q2 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
22021000000 USD
CY2019Q2 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
24486000000 USD
CY2020Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
2776000000 USD
CY2020Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
1594000000 USD
CY2020Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
3630000000 USD
CY2020Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
746000000 USD
CY2020Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
2704000000 USD
CY2020Q2 us-gaap Long Term Debt Maturities Repayments Of Principal After Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
13466000000 USD
CY2020Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
24916000000 USD
CY2020Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
2776000000 USD
CY2020Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
22140000000 USD
CY2020Q2 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
27100000000 USD
CY2020Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
24500000000 USD
CY2019Q2 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
26200000000 USD
CY2019Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
25000000000.0 USD
CY2020Q2 mdt Unrealized Gain Loss On Interest Rate Cash Flow Hedges Accumulated Other Comprehensive Income Loss Net Of Tax
UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax
266000000 USD
CY2019Q2 mdt Unrealized Gain Loss On Interest Rate Cash Flow Hedges Accumulated Other Comprehensive Income Loss Net Of Tax
UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax
194000000 USD
CY2020 us-gaap Cash Flow Hedge Gain Loss To Be Reclassified Within Twelve Months
CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths
225000000 USD
CY2018 us-gaap Gain Loss From Hedged Firm Commitment Not Qualifying As Fair Value Hedge Net
GainLossFromHedgedFirmCommitmentNotQualifyingAsFairValueHedgeNet
0 USD
CY2020 us-gaap Gain Loss From Hedged Firm Commitment Not Qualifying As Fair Value Hedge Net
GainLossFromHedgedFirmCommitmentNotQualifyingAsFairValueHedgeNet
0 USD
CY2019 us-gaap Gain Loss From Hedged Firm Commitment Not Qualifying As Fair Value Hedge Net
GainLossFromHedgedFirmCommitmentNotQualifyingAsFairValueHedgeNet
0 USD
CY2020 us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
126000000 USD
CY2019 us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
236000000 USD
CY2018 us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
-226000000 USD
CY2020 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-71000000 USD
CY2019 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-258000000 USD
CY2018 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-535000000 USD
CY2020 mdt Unrealized Gain Losson Net Investment Hedges Accumulated Other Comprehensive Income Loss Netof Tax
UnrealizedGainLossonNetInvestmentHedgesAccumulatedOtherComprehensiveIncomeLossNetofTax
236000000 USD
CY2019 mdt Unrealized Gain Losson Net Investment Hedges Accumulated Other Comprehensive Income Loss Netof Tax
UnrealizedGainLossonNetInvestmentHedgesAccumulatedOtherComprehensiveIncomeLossNetofTax
-169000000 USD
CY2020 mdt Net Investment Hedge Gain Losstobe Reclassified Within Twelve Months
NetInvestmentHedgeGainLosstobeReclassifiedWithinTwelveMonths
0 USD
CY2018 mdt Gain Lossfrom Hedged Firm Commitment Not Qualifyingas Net Investment Hedge Net
GainLossfromHedgedFirmCommitmentNotQualifyingasNetInvestmentHedgeNet
0 USD
CY2020 mdt Gain Lossfrom Hedged Firm Commitment Not Qualifyingas Net Investment Hedge Net
GainLossfromHedgedFirmCommitmentNotQualifyingasNetInvestmentHedgeNet
0 USD
CY2019 mdt Gain Lossfrom Hedged Firm Commitment Not Qualifyingas Net Investment Hedge Net
GainLossfromHedgedFirmCommitmentNotQualifyingasNetInvestmentHedgeNet
0 USD
CY2020Q2 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
402000000 USD
CY2020Q2 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
42000000 USD
CY2019Q2 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
365000000 USD
CY2019Q2 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
19000000 USD
CY2020Q2 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
402000000 USD
CY2020Q2 us-gaap Derivative Asset Not Offset Policy Election Deduction
DerivativeAssetNotOffsetPolicyElectionDeduction
17000000 USD
CY2020Q2 us-gaap Derivative Collateral Obligation To Return Cash
DerivativeCollateralObligationToReturnCash
48000000 USD
CY2020Q2 us-gaap Derivative Fair Value Of Derivative Asset Amount Offset Against Collateral
DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral
337000000 USD
CY2020Q2 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
42000000 USD
CY2020Q2 us-gaap Derivative Liability Not Offset Policy Election Deduction
DerivativeLiabilityNotOffsetPolicyElectionDeduction
17000000 USD
CY2020Q2 us-gaap Derivative Collateral Right To Reclaim Cash
DerivativeCollateralRightToReclaimCash
0 USD
CY2020Q2 us-gaap Derivative Fair Value Of Derivative Liability Amount Offset Against Collateral
DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral
25000000 USD
CY2020Q2 mdt Derivative Asset Liability Fair Value Gross Asset Liability
DerivativeAssetLiabilityFairValueGrossAssetLiability
360000000 USD
CY2020Q2 mdt Derivative Assetsand Liabilities Net Not Offset Policy Election Deduction
DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction
0 USD
CY2020Q2 mdt Derivative Assetsand Liabilities Net Collateral Obligationto Return Cash
DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash
48000000 USD
CY2020Q2 us-gaap Derivative Fair Value Amount Offset Against Collateral Net
DerivativeFairValueAmountOffsetAgainstCollateralNet
312000000 USD
CY2019Q2 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
365000000 USD
CY2019Q2 us-gaap Derivative Asset Not Offset Policy Election Deduction
DerivativeAssetNotOffsetPolicyElectionDeduction
9000000 USD
CY2019Q2 us-gaap Derivative Collateral Obligation To Return Cash
DerivativeCollateralObligationToReturnCash
44000000 USD
CY2019Q2 us-gaap Derivative Fair Value Of Derivative Asset Amount Offset Against Collateral
DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral
312000000 USD
CY2019Q2 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
19000000 USD
CY2019Q2 us-gaap Derivative Liability Not Offset Policy Election Deduction
DerivativeLiabilityNotOffsetPolicyElectionDeduction
9000000 USD
CY2019Q2 us-gaap Derivative Collateral Right To Reclaim Cash
DerivativeCollateralRightToReclaimCash
0 USD
CY2019Q2 us-gaap Derivative Fair Value Of Derivative Liability Amount Offset Against Collateral
DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral
10000000 USD
CY2019Q2 mdt Derivative Asset Liability Fair Value Gross Asset Liability
DerivativeAssetLiabilityFairValueGrossAssetLiability
346000000 USD
CY2019Q2 mdt Derivative Assetsand Liabilities Net Not Offset Policy Election Deduction
DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction
0 USD
CY2019Q2 mdt Derivative Assetsand Liabilities Net Collateral Obligationto Return Cash
DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash
44000000 USD
CY2019Q2 us-gaap Derivative Fair Value Amount Offset Against Collateral Net
DerivativeFairValueAmountOffsetAgainstCollateralNet
302000000 USD
CY2020Q2 mdt Derivative Assetsand Liabilities Net Collateral Obligationto Return Cash
DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash
48000000 USD
CY2019Q2 mdt Derivative Assetsand Liabilities Net Collateral Obligationto Return Cash
DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash
44000000 USD
CY2020Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2874000000 USD
CY2019Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2476000000 USD
CY2020Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
608000000 USD
CY2019Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
572000000 USD
CY2020Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
747000000 USD
CY2019Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
705000000 USD
CY2020Q2 us-gaap Inventory Net
InventoryNet
4229000000 USD
CY2019Q2 us-gaap Inventory Net
InventoryNet
3753000000 USD
CY2018Q2 us-gaap Goodwill
Goodwill
39543000000 USD
CY2019 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
1510000000 USD
CY2019 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-1094000000 USD
CY2019Q2 us-gaap Goodwill
Goodwill
39959000000 USD
CY2020 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
333000000 USD
CY2020 us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
124000000 USD
CY2020 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-575000000 USD
CY2020Q2 us-gaap Goodwill
Goodwill
39841000000 USD
CY2018 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2019 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2020 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2020Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
28244000000 USD
CY2020Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
9704000000 USD
CY2019Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
29004000000 USD
CY2019Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
9048000000 USD
CY2020 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
37000000 USD
CY2019 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
87000000 USD
CY2018 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 USD
CY2020 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
35000000 USD
CY2019 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
30000000 USD
CY2018 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1800000000 USD
CY2019 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1800000000 USD
CY2020 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1800000000 USD
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1748000000 USD
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1706000000 USD
CY2017Q2 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
5000000000.0 USD
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1644000000 USD
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1615000000 USD
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
1588000000 USD
CY2020Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11644000000 USD
CY2019Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10920000000 USD
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6816000000 USD
CY2019Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6245000000 USD
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4828000000 USD
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4675000000 USD
CY2020 us-gaap Depreciation
Depreciation
907000000 USD
CY2019 us-gaap Depreciation
Depreciation
895000000 USD
CY2018 us-gaap Depreciation
Depreciation
821000000 USD
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2600000000 shares
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q2 mdt Deferred Stock Shares Authorized
DeferredStockSharesAuthorized
40000 shares
CY2020Q2 mdt Deferred Stock Paror Stated Value Per Share
DeferredStockParorStatedValuePerShare
1.00
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
127500000 shares
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.20
CY2020Q2 mdt Deferred Stock Shares Authorized
DeferredStockSharesAuthorized
40000 shares
CY2020Q2 mdt Deferred Stock Paror Stated Value Per Share
DeferredStockParorStatedValuePerShare
1.00
CY2020Q2 mdt Deferred Stock Shares Outstanding
DeferredStockSharesOutstanding
0 shares
CY2020Q2 mdt Deferred Stock Shares Issued
DeferredStockSharesIssued
0 shares
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
127500000 shares
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.20
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
12000000 shares
CY2019 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
31000000 shares
CY2020 mdt Stock Repurchase Program Average Purchase Price
StockRepurchaseProgramAveragePurchasePrice
106.22
CY2019 mdt Stock Repurchase Program Average Purchase Price
StockRepurchaseProgramAveragePurchasePrice
91.43
CY2020Q2 us-gaap Stock Repurchase Program Remaining Authorized Repurchase Amount1
StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
6000000000.0 USD
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.1951
us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
5000000000.0 USD
CY2019Q1 mdt Stock Repurchase Program Additional Authorized Amount
StockRepurchaseProgramAdditionalAuthorizedAmount
6000000000.0 USD
CY2020Q2 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
11000000000.0 USD
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
15.49
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
14.77
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
13.71
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y2M12D
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0188
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0290
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0200
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.1797
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.1777
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0209
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0225
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0219
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
297000000 USD
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
290000000 USD
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
344000000 USD
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
297000000 USD
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
290000000 USD
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
344000000 USD
CY2020 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
51000000 USD
CY2019 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
54000000 USD
CY2018 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
82000000 USD
CY2020 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
246000000 USD
CY2019 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
236000000 USD
CY2018 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
262000000 USD
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
466000000 USD
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
877000000 USD
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-958000000 USD
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
3589000000 USD
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
4320000000 USD
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
6633000000 USD
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
4055000000 USD
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
5197000000 USD
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
5675000000 USD
CY2020 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
151000000 USD
CY2019 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
579000000 USD
CY2018 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
2899000000 USD
CY2020 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
375000000 USD
CY2019 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
406000000 USD
CY2018 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
796000000 USD
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
526000000 USD
CY2019 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
985000000 USD
CY2018 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
3695000000 USD
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-138000000 USD
CY2019 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-310000000 USD
CY2018 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
45000000 USD
CY2020 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-1139000000 USD
CY2019 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-128000000 USD
CY2018 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-1160000000 USD
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1277000000 USD
CY2019 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-438000000 USD
CY2018 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1115000000 USD
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-751000000 USD
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
547000000 USD
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2580000000 USD
CY2020Q2 mdt Deferred Tax Assets Operating And Capital Losses And Tax Credit Carryforwards
DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards
6432000000 USD
CY2019Q2 mdt Deferred Tax Assets Operating And Capital Losses And Tax Credit Carryforwards
DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards
6574000000 USD
CY2020Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
390000000 USD
CY2019Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
389000000 USD
CY2020Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
285000000 USD
CY2019Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
315000000 USD
CY2020Q2 mdt Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Postretirement Benefits And Pensions
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefitsAndPensions
350000000 USD
CY2019Q2 mdt Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Postretirement Benefits And Pensions
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefitsAndPensions
300000000 USD
CY2020Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
136000000 USD
CY2019Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
162000000 USD
CY2020Q2 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
338000000 USD
CY2019Q2 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
339000000 USD
CY2020Q2 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
191000000 USD
CY2019Q2 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
194000000 USD
CY2020Q2 mdt Deferred Tax Assets Lease Obligations
DeferredTaxAssetsLeaseObligations
101000000 USD
CY2020Q2 mdt Deferred Tax Assets Tax Deferred Expense Federal And State Benefit On Uncertain Tax Positions
DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions
96000000 USD
CY2019Q2 mdt Deferred Tax Assets Tax Deferred Expense Federal And State Benefit On Uncertain Tax Positions
DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions
83000000 USD
CY2020Q2 mdt Deferred Tax Assets Interest Limitation
DeferredTaxAssetsInterestLimitation
236000000 USD
CY2019Q2 mdt Deferred Tax Assets Interest Limitation
DeferredTaxAssetsInterestLimitation
111000000 USD
CY2020Q2 mdt Deferred Tax Assets Unrealized Losses On Available For Sale Securities And Derivative Financial Instruments
DeferredTaxAssetsUnrealizedLossesOnAvailableForSaleSecuritiesAndDerivativeFinancialInstruments
0 USD
CY2019Q2 mdt Deferred Tax Assets Unrealized Losses On Available For Sale Securities And Derivative Financial Instruments
DeferredTaxAssetsUnrealizedLossesOnAvailableForSaleSecuritiesAndDerivativeFinancialInstruments
17000000 USD
CY2020Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
8555000000 USD
CY2019Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
8484000000 USD
CY2020Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
5482000000 USD
CY2019Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
6300000000 USD
CY2020Q2 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
3073000000 USD
CY2019Q2 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
2184000000 USD
CY2020Q2 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
1017000000 USD
CY2020Q2 us-gaap Income Tax Receivable
IncomeTaxReceivable
381000000 USD
CY2019Q2 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
1614000000 USD
CY2020Q2 us-gaap Deferred Tax Liabilities Derivatives
DeferredTaxLiabilitiesDerivatives
65000000 USD
CY2019Q2 us-gaap Deferred Tax Liabilities Derivatives
DeferredTaxLiabilitiesDerivatives
70000000 USD
CY2020Q2 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
110000000 USD
CY2019Q2 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
152000000 USD
CY2020Q2 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
97000000 USD
CY2020Q2 mdt Deferred Tax Liabilities Unrealized Gains On Trading Securities And Derivatives
DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecuritiesAndDerivatives
12000000 USD
CY2019Q2 mdt Deferred Tax Liabilities Unrealized Gains On Trading Securities And Derivatives
DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecuritiesAndDerivatives
0 USD
CY2020Q2 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
87000000 USD
CY2019Q2 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
38000000 USD
CY2020Q2 mdt Deferred Tax Liabilities Investment In Subsidiaries
DeferredTaxLiabilitiesInvestmentInSubsidiaries
77000000 USD
CY2019Q2 mdt Deferred Tax Liabilities Investment In Subsidiaries
DeferredTaxLiabilitiesInvestmentInSubsidiaries
119000000 USD
CY2020Q2 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1465000000 USD
CY2019Q2 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1993000000 USD
CY2020Q2 us-gaap Prepaid Taxes
PrepaidTaxes
449000000 USD
CY2019Q2 us-gaap Prepaid Taxes
PrepaidTaxes
363000000 USD
CY2019Q2 us-gaap Income Tax Receivable
IncomeTaxReceivable
335000000 USD
CY2020Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
2438000000 USD
CY2019Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
889000000 USD
CY2020Q2 mdt Deferred Tax Assets Netof Valuation Allowance Other
DeferredTaxAssetsNetofValuationAllowanceOther
780000000 USD
CY2019Q2 mdt Deferred Tax Assets Netof Valuation Allowance Other
DeferredTaxAssetsNetofValuationAllowanceOther
648000000 USD
CY2020Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
2832000000 USD
CY2019Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
1519000000 USD
CY2020Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1174000000 USD
CY2019Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1278000000 USD
CY2020Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
2438000000 USD
CY2019Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
889000000 USD
CY2020Q2 us-gaap Undistributed Earnings Of Foreign Subsidiaries
UndistributedEarningsOfForeignSubsidiaries
69900000000 USD
CY2019Q2 us-gaap Undistributed Earnings Of Foreign Subsidiaries
UndistributedEarningsOfForeignSubsidiaries
64100000000 USD
CY2020Q2 us-gaap Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
200000000 USD
CY2020Q2 mdt Deferred Tax Assets Tax Credit Carryforwards Not Subjectto Expiration
DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration
96000000 USD
CY2020Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
5500000000 USD
CY2019Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
6300000000 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.305
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.005
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.009
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.008
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.021
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.012
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.008
CY2020 mdt Effective Income Tax Rate Reconciliation Puerto Rico Excise Tax
EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax
0.015
CY2019 mdt Effective Income Tax Rate Reconciliation Puerto Rico Excise Tax
EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax
0.016
CY2018 mdt Effective Income Tax Rate Reconciliation Puerto Rico Excise Tax
EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax
0.011
CY2020 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.100
CY2019 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.107
CY2018 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.189
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.002
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.430
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.015
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.010
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.010
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.004
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.005
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.016
CY2020 mdt Effective Income Tax Rate Reconciliation Interest On Uncertain Tax Positions Percent
EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent
0.013
CY2019 mdt Effective Income Tax Rate Reconciliation Interest On Uncertain Tax Positions Percent
EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent
0.009
CY2018 mdt Effective Income Tax Rate Reconciliation Interest On Uncertain Tax Positions Percent
EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent
0.014
CY2020 mdt Effective Income Tax Rate Reconciliation Base Erosion And Anti Abuse Tax Percent
EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent
0.026
CY2019 mdt Effective Income Tax Rate Reconciliation Base Erosion And Anti Abuse Tax Percent
EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent
0.001
CY2018 mdt Effective Income Tax Rate Reconciliation Base Erosion And Anti Abuse Tax Percent
EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent
0
CY2020 mdt Effective Income Tax Rate Reconciliation Deduction Foreign Derived Intangible Income Percent
EffectiveIncomeTaxRateReconciliationDeductionForeignDerivedIntangibleIncomePercent
0.012
CY2019 mdt Effective Income Tax Rate Reconciliation Deduction Foreign Derived Intangible Income Percent
EffectiveIncomeTaxRateReconciliationDeductionForeignDerivedIntangibleIncomePercent
0.006
CY2018 mdt Effective Income Tax Rate Reconciliation Deduction Foreign Derived Intangible Income Percent
EffectiveIncomeTaxRateReconciliationDeductionForeignDerivedIntangibleIncomePercent
0
CY2020 us-gaap Effective Income Tax Rate Reconciliation Disposition Of Business
EffectiveIncomeTaxRateReconciliationDispositionOfBusiness
0
CY2019 us-gaap Effective Income Tax Rate Reconciliation Disposition Of Business
EffectiveIncomeTaxRateReconciliationDispositionOfBusiness
-0.004
CY2018 us-gaap Effective Income Tax Rate Reconciliation Disposition Of Business
EffectiveIncomeTaxRateReconciliationDispositionOfBusiness
-0.038
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.308
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.006
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.089
CY2020 us-gaap Effective Income Tax Rate Reconciliation Repatriation Of Foreign Earnings
EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings
0.028
CY2019 us-gaap Effective Income Tax Rate Reconciliation Repatriation Of Foreign Earnings
EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings
0.040
CY2018 us-gaap Effective Income Tax Rate Reconciliation Repatriation Of Foreign Earnings
EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings
0.027
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.185
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.105
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.455
CY2020 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
-1200000000 USD
CY2020 us-gaap Tax Cuts And Jobs Act Of2017 Measurement Period Adjustment Income Tax Expense Benefit
TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit
-63000000 USD
CY2020 us-gaap Income Tax Reconciliation Tax Contingencies Foreign
IncomeTaxReconciliationTaxContingenciesForeign
-252000000 USD
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-658000000 USD
CY2020 mdt Tax Expense Benefit Associated With Saleof Intellectual Property
TaxExpenseBenefitAssociatedWithSaleofIntellectualProperty
-269000000 USD
CY2019 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
-40000000 USD
CY2019 us-gaap Tax Cuts And Jobs Act Of2017 Measurement Period Adjustment Income Tax Expense Benefit
TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit
-30000000 USD
CY2019 us-gaap Tax Cuts And Jobs Act Of2017 Change In Tax Rate Deferred Tax Asset Income Tax Expense
TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetIncomeTaxExpense
42000000 USD
CY2019 mdt Tax Expense Benefit Associated With Intercompany Legal Entity Restructuring
TaxExpenseBenefitAssociatedWithIntercompanyLegalEntityRestructuring
-32000000 USD
CY2019 us-gaap Income Tax Reconciliation Disposition Of Business
IncomeTaxReconciliationDispositionOfBusiness
-20000000 USD
CY2018 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
1900000000 USD
CY2018 us-gaap Tax Cuts And Jobs Act Of2017 Income Tax Expense Benefit
TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit
2400000000 USD
CY2018 us-gaap Income Tax Reconciliation Nondeductible Expense Restructuring Charges
IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges
73000000 USD
CY2018 mdt Tax Expense Benefit Associated With Saleof Intellectual Property
TaxExpenseBenefitAssociatedWithSaleofIntellectualProperty
-579000000 USD
CY2020 us-gaap Income Tax Reconciliation Tax Holidays
IncomeTaxReconciliationTaxHolidays
231000000 USD
CY2019 us-gaap Income Tax Reconciliation Tax Holidays
IncomeTaxReconciliationTaxHolidays
437000000 USD
CY2018 us-gaap Income Tax Reconciliation Tax Holidays
IncomeTaxReconciliationTaxHolidays
446000000 USD
CY2020Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1900000000 USD
CY2019Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1800000000 USD
CY2018Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1700000000 USD
CY2019Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1836000000 USD
CY2018Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1727000000 USD
CY2017Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1896000000 USD
CY2019Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1836000000 USD
CY2018Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1727000000 USD
CY2020 mdt Cash Advance Paidin Connection With Proposed Settlements
CashAdvancePaidinConnectionWithProposedSettlements
859000000 USD
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
12000000 USD
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
34000000 USD
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
13000000 USD
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
55000000 USD
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
109000000 USD
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
63000000 USD
CY2020 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
9000000 USD
CY2019 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
14000000 USD
CY2018 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
120000000 USD
CY2020 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
5000000 USD
CY2019 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
0 USD
CY2018 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
80000000 USD
CY2020 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
27000000 USD
CY2019 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
20000000 USD
CY2018 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
45000000 USD
CY2020Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1862000000 USD
CY2019 mdt Cash Advance Paidin Connection With Proposed Settlements
CashAdvancePaidinConnectionWithProposedSettlements
859000000 USD
CY2018 mdt Cash Advance Paidin Connection With Proposed Settlements
CashAdvancePaidinConnectionWithProposedSettlements
859000000 USD
CY2020Q2 mdt Unrecognized Tax Benefits Netof Cash Advance Paid
UnrecognizedTaxBenefitsNetofCashAdvancePaid
1003000000 USD
CY2019Q2 mdt Unrecognized Tax Benefits Netof Cash Advance Paid
UnrecognizedTaxBenefitsNetofCashAdvancePaid
977000000 USD
CY2018Q2 mdt Unrecognized Tax Benefits Netof Cash Advance Paid
UnrecognizedTaxBenefitsNetofCashAdvancePaid
868000000 USD
CY2020Q2 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
1800000000 USD
CY2019Q2 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
1800000000 USD
CY2018Q2 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
1700000000 USD
CY2020Q2 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
911000000 USD
CY2020Q2 us-gaap Decrease In Unrecognized Tax Benefits Is Reasonably Possible
DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
115000000 USD
CY2020Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
225000000 USD
CY2019Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
172000000 USD
CY2018Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
128000000 USD
CY2020 us-gaap Income Tax Examination Interest Expense
IncomeTaxExaminationInterestExpense
53000000 USD
CY2019 us-gaap Income Tax Examination Interest Expense
IncomeTaxExaminationInterestExpense
48000000 USD
CY2018 us-gaap Income Tax Examination Interest Expense
IncomeTaxExaminationInterestExpense
84000000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
4789000000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
4631000000 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
3104000000 USD
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1340700000 shares
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1346400000 shares
CY2018 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1356700000 shares
CY2020 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
7200000 shares
CY2019 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
7600000 shares
CY2018 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
7900000 shares
CY2020 us-gaap Incremental Common Shares Attributable To Nonvested Shares With Forfeitable Dividends
IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends
2800000 shares
CY2019 us-gaap Incremental Common Shares Attributable To Nonvested Shares With Forfeitable Dividends
IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends
3200000 shares
CY2018 us-gaap Incremental Common Shares Attributable To Nonvested Shares With Forfeitable Dividends
IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends
3300000 shares
CY2020 mdt Incremental Common Shares Attributableto Dilutive Effectof Other Shares
IncrementalCommonSharesAttributabletoDilutiveEffectofOtherShares
400000 shares
CY2019 mdt Incremental Common Shares Attributableto Dilutive Effectof Other Shares
IncrementalCommonSharesAttributabletoDilutiveEffectofOtherShares
300000 shares
CY2018 mdt Incremental Common Shares Attributableto Dilutive Effectof Other Shares
IncrementalCommonSharesAttributabletoDilutiveEffectofOtherShares
300000 shares
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1351100000 shares
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1357500000 shares
CY2018 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1368200000 shares
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.57
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.44
CY2018 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.29
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.54
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.41
CY2018 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.27
CY2020 us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
467000000 USD
CY2019 us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
539000000 USD
CY2018 us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
552000000 USD
CY2020Q2 us-gaap Defined Benefit Plan Funded Status Of Plan
DefinedBenefitPlanFundedStatusOfPlan
-1400000000 USD
CY2019Q2 us-gaap Defined Benefit Plan Funded Status Of Plan
DefinedBenefitPlanFundedStatusOfPlan
-1100000000 USD
CY2020Q2 mdt Investments Numberof Investments In Processof Liquidation
InvestmentsNumberofInvestmentsInProcessofLiquidation
0 fund
CY2020 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
376000000 USD
CY2019 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
415000000 USD
CY2018 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
374000000 USD
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
927000000 USD
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y2M12D
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
171000000 USD
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
774000000 USD
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.030
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
223000000 USD
CY2020 us-gaap Short Term Lease Cost
ShortTermLeaseCost
46000000 USD
CY2020 us-gaap Lease Cost
LeaseCost
269000000 USD
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
221000000 USD
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
174000000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
218000000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
175000000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
144000000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
118000000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
102000000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
277000000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1034000000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
89000000 USD
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
945000000 USD
CY2019Q2 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
216000000 USD
CY2019Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
157000000 USD
CY2019Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
103000000 USD
CY2019Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
61000000 USD
CY2019Q2 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
34000000 USD
CY2019Q2 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
81000000 USD
CY2019Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
652000000 USD
CY2019 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
305000000 USD
CY2018 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
319000000 USD
CY2020 us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
Commitments and Contingencies <div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Legal Matters</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company and its affiliates are involved in a number of legal actions involving product liability, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, tax disputes, and governmental proceedings and investigations, including those described below. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state and local governmental agencies in the United States and in other jurisdictions in which the Company and its affiliates operate. As a result, interaction with governmental agencies is ongoing. The Company’s standard practice is to cooperate with regulators and investigators in responding to inquiries. The outcomes of legal actions are not within the Company’s complete control and may not be known for prolonged periods of time. In some actions, the enforcement agencies or private claimants seek damages, as well as other civil or criminal remedies (including injunctions barring the sale of products that are the subject of the proceeding), that could require significant expenditures, result in lost revenues, or limit the Company's ability to conduct business in the applicable jurisdictions.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required. Estimates of probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages with incomplete scientific facts or legal discovery, involve unsubstantiated or indeterminate claims for damages, potentially involve penalties, fines or punitive damages, or could result in a change in business practice. The Company classifies litigation charges and gains related to significant legal matters as certain litigation charges. During fiscal years 2020, 2019, and 2018, the Company recognized $313 million, $166 million, and $61 million, respectively, of certain litigation charges. At both April 24, 2020 and April 26, 2019, accrued litigation was approximately $0.5 billion. The ultimate cost to the Company with respect to accrued litigation could be materially different than the amount of the current estimates and accruals and could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows. The Company includes accrued litigation in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">other accrued expenses</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">other liabilities</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> on the consolidated balance sheets. While it is not possible to predict the outcome for most of the legal matters discussed below, the Company believes it is possible that the costs associated with these matters could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Product Liability Matters</span></div><div style="text-align:justify;margin-top:9pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Pelvic Mesh Litigation</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is currently involved in litigation in various state and federal courts against manufacturers of pelvic mesh products alleging personal injuries resulting from the implantation of those products. Two subsidiaries of Covidien supplied pelvic mesh products to one of the manufacturers, C.R. Bard (Bard), named in the litigation. The litigation includes a federal multi-district litigation in the U.S. District Court for the Northern District of West Virginia and cases in various state courts and jurisdictions outside the U.S. Generally, complaints allege design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. In fiscal year 2016, Bard paid the Company $121 million towards the settlement of 11,000 of these claims. In May 2017, the agreement with Bard was amended to extend the terms to apply to up to an additional 5,000 claims. That agreement does not resolve the dispute between the Company and Bard with respect to claims that do not settle, if any. As part of the agreement, the Company and Bard agreed to dismiss without prejudice their pending litigation with respect to Bard’s obligation to defend and indemnify the Company. The Company estimates law firms representing approximately 16,200 claimants have asserted or may assert claims involving products manufactured by Covidien’s subsidiaries. As of June 3, 2020, the Company had reached agreements to settle </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">approximately 15,900 of these claims. The Company's accrued expenses for this matter are included within accrued litigation as discussed above.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Hernia Mesh Litigation</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During fiscal year 2020, plaintiffs filed lawsuits against certain subsidiaries of the Company in U.S. state and federal courts alleging personal injury from hernia mesh products sold by those subsidiaries. The majority of the pending cases are in Massachusetts state court, and a motion for consolidation of those cases was filed during the fourth quarter of fiscal year 2020. Certain plaintiffs law firms have advised the Company that they may file additional cases in the future. The pending lawsuits relate to hernia mesh products that have not been subject to recalls, withdrawals or other adverse regulatory action. The Company has not recorded an expense related to damages in connection with these matters because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Patent Litigation</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Ethicon</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On December 14, 2011, Ethicon filed an action against Covidien in the U.S. District Court for the Southern District of Ohio, alleging patent infringement and seeking monetary damages and injunctive relief. On January 22, 2014, the district court entered summary judgment in Covidien's favor, and the majority of this ruling was affirmed by the Federal Circuit on August 7, 2015. Following appeal, the case was remanded back to the District Court with respect to one patent. On January 21, 2016, Covidien filed a second action in the U.S. District Court for the Southern District of Ohio, seeking a declaration of non-infringement with respect to a second set of patents held by Ethicon. The court consolidated this second action with the remaining patent issues from the first action. Following consolidation of the cases, Ethicon dismissed six of the asserted patents, leaving a single asserted patent. In addition to claims of non-infringement, the Company asserts an affirmative defense of invalidity. The Company has not recognized an expense related to damages in connection with this matter, because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from this matter.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Sasso</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company is involved in litigation in Indiana relating to certain patent and royalty disputes with Dr. Sasso under agreements originally entered into in 1999 and 2001. On November 28, 2018, a jury in Indiana state court returned a verdict against the Company for approximately $112 million. The Company has strong arguments to appeal the verdict and has filed post-trial motions and appeals with the appropriate appellate courts. The Company's accrued expenses for this matter are included within accrued litigation as discussed above.</span></div><div style="text-align:justify;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Shareholder Related Matters</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Covidien Acquisition</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On July 2, 2014, Lewis Merenstein filed a putative shareholder class action in Hennepin County, Minnesota, District Court seeking to enjoin the then-potential acquisition of Covidien. The lawsuit named Medtronic, Inc., Covidien, and each member of the Medtronic, Inc. Board of Directors at the time as defendants, and alleged that the directors breached their fiduciary duties to shareholders with regard to the then-potential acquisition. On August 21, 2014, Kenneth Steiner filed a putative shareholder class action in Hennepin County, Minnesota, District Court, also seeking an injunction to prevent the potential Covidien acquisition. In September 2014, the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Merenstein</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Steiner</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> matters were consolidated and in December 2014, the plaintiffs filed a preliminary injunction motion seeking to enjoin the Covidien transaction. On March 20, 2015, the District Court issued an order and opinion granting Medtronic’s motion to dismiss the case. In May of 2015, the plaintiffs filed an appeal, and, in January of 2016, the Minnesota State Court of Appeals affirmed in part, and reversed in part. On April 19, 2016, the Minnesota Supreme Court granted the Company’s petition to review the issue of whether most of the original claims are properly characterized as direct or derivative under Minnesota law. In August of 2017, the Minnesota Supreme Court affirmed the decision of the Minnesota State Court of Appeals, sending the matter back to the trial court for further proceedings, which are ongoing. In April of 2020, the District Court issued an order and opinion denying the plaintiffs' motion for class certification. The Company has not recognized an expense related to damages in connection with this matter, because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Environmental Proceedings</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is involved in various stages of investigation and cleanup related to environmental remediation matters at a number of sites. These projects relate to a variety of activities, including removal of solvents, metals and other hazardous substances from soil and groundwater. The ultimate cost of site cleanup and timing of future cash flows is difficult to predict given uncertainties regarding the extent of the required cleanup, the interpretation of applicable laws and regulations, and alternative cleanup methods.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is a successor to a company which owned and operated a chemical manufacturing facility in Orrington, Maine from 1967 until 1982, and is responsible for the costs of completing an environmental site investigation as required by the Maine Department of Environmental Protection (MDEP). MDEP served a compliance order on Mallinckrodt LLC and U.S. Surgical Corporation, subsidiaries of Covidien, in December 2008, which included a directive to remove a significant volume of soils at the site. After a hearing on the compliance order before the Maine Board of Environmental Protection (Maine Board) to challenge the terms of the compliance order, the Maine Board modified the MDEP order and issued a final order requiring removal of two landfills, capping of the remaining three landfills, installation of a groundwater extraction system and long-term monitoring of the site and the three remaining landfills.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has proceeded with implementation of the investigation and remediation at the site in accordance with the MDEP order as modified by the Maine Board order.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since the early 2000s, the Company or its predecessors have also been involved in a lawsuit filed in the U.S. District Court for the District of Maine by the Natural Resources Defense Council and the Maine People’s Alliance. Plaintiffs sought an injunction requiring the Company's predecessor to conduct extensive studies of mercury contamination of the Penobscot River and Bay and options for remediating such contamination, and to perform appropriate remedial activities, if necessary.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Following a trial in March 2002, the Court held that conditions in the Penobscot River and Bay may pose an imminent and substantial endangerment and that the Company’s predecessor was liable for the cost of performing a study of the River and Bay. Following a second trial in June 2014, the Court ordered that further engineering study and engineering design work was needed to determine the nature and extent of remediation in the Penobscot River and Bay. The Court also appointed an engineering firm to conduct such studies and issue a report on potential remediation alternatives. In connection with these proceedings, reports have been produced including a variety of cost estimates for a variety of potential remedial options. A third trial to determine the course of remediation to be pursued is scheduled to occur in fiscal year 2021.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's accrued expenses for environmental proceedings are included within accrued litigation as discussed above.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Government Matters</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since 2017, the Company has been responding to requests from the Department of Justice and U.S. Department of Health and Human Services for information about business practices relating to a neurovascular product developed and first marketed by ev3 and Covidien. The Company has provided information in response to these requests and is cooperating with the inquiry. The Company has not recognized an expense in connection with any ongoing investigation, because any such potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from the ongoing information requests.</span></div><div style="text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Income Taxes </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2009, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2005 and 2006. Medtronic, Inc. reached agreement with the IRS on some, but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2005 and 2006 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, which is one of the Company's key manufacturing sites. The U.S. Tax Court reviewed this dispute, and on June 9, 2016, issued its opinion with respect to the allocation of income between the parties for fiscal years 2005 and 2006. The U.S. Tax Court generally rejected the IRS’s position, but also made certain modifications to the Medtronic, Inc. tax returns as filed. On April 21, 2017, the IRS filed their Notice of Appeal to the U.S. Court of Appeals for the 8th Circuit regarding the Tax Court Opinion. Oral argument for the Appeal occurred on March 14, 2018. The 8th Circuit Court of Appeals issued their opinion on August 16, 2018, and remanded the case back to the U.S. Tax Court for additional factual findings. The U.S. Tax Court scheduled for April of 2020 was postponed due to the challenges of COVID-19. The new trial date has not been re-scheduled.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2011, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2007 and 2008. Medtronic, Inc. reached agreement with the IRS on some, but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2007 and 2008 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for the businesses that are the subject of the U.S. Tax Court Case for fiscal years 2005 and 2006. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2014, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2009, 2010, and 2011. Medtronic, Inc. reached agreement with the IRS on some but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2009, 2010, and 2011 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for the businesses that are the subject of the U.S. Tax Court Case for fiscal years 2005 and 2006. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2017, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2012, 2013, and 2014. Medtronic, Inc. reached agreement with the IRS on some but not all matters related to these fiscal years. The significant issues that remain unresolved relate to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, and proposed adjustments associated with the utilization of certain net operating losses. The Company disagrees with the IRS and will attempt to resolve these matters at the IRS Appellate level.</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Medtronic, Inc.’s fiscal years 2015 and 2016 U.S. federal income tax returns are currently being audited by the IRS.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Covidien and the IRS have concluded and reached agreement on its audit of Covidien’s U.S. federal income tax returns for all tax years through 2012. The statute of limitations for Covidien’s 2013 and 2014 U.S. federal income tax returns lapsed during the first quarter of fiscal years 2018 and 2019, respectively. Covidien's fiscal year 2015 U.S. federal income tax returns are currently being audited by the IRS. The statute of limitations for Covidien's 2016 U.S. federal income tax return lapsed during the third quarter of fiscal year 2020.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While it is not possible to predict the outcome for most of the income tax matters discussed above, the Company believes it is possible that charges associated with these matters could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See Note 14 for additional discussion of income taxes.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Guarantees</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a result of the acquisition of Covidien, the Company had a guarantee commitment related to certain contingent tax liabilities as a party to the Tax Sharing Agreement that was entered into on June 29, 2007, between Covidien, Tyco International (now Johnson Controls), and Tyco Electronics (now TE Connectivity), associated with the spin-off from Tyco. The Tax Sharing Agreement covered certain income tax liabilities for periods prior to and including the spin-off. Medtronic’s share of the income tax liabilities for these periods was 42 percent, with Johnson Controls and TE Connectivity share being 27 percent, and 31 percent, respectively. If Johnson Controls and TE Connectivity default on their obligations to the Company under the Tax Sharing Agreement, the Company would be liable for the entire amount of these liabilities. All costs and expenses associated with the management of these tax liabilities were being shared equally among the parties. The most significant amounts at risk under this Tax Sharing Agreement were resolved with the U.S. Tax Court and IRS Appeals resolutions reached in May 2016. The parties terminated the Tax Sharing Agreement during the fourth quarter of fiscal year 2020.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of the Company’s sale of the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses to Cardinal on July 29, 2017, the Company has indemnified Cardinal for certain contingent tax liabilities related to the divested businesses that existed prior to the date of divestiture. The actual amounts that the Company may be required to ultimately accrue or pay could vary depending upon the outcome of the unresolved tax matters.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the normal course of business, the Company and/or its affiliates periodically enter into agreements that require one or more of the Company and/or its affiliates to indemnify customers or suppliers for specific risks, such as claims for injury or property damage arising as a result of the Company or its affiliates’ products, the negligence of the Company's personnel, or claims alleging that the Company's products infringe on third-party patents or other intellectual property. The Company also offers warranties on various products. The Company’s maximum exposure under these guarantees is unable to be estimated. Historically, the Company has not experienced significant losses on these types of guarantees.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company believes the ultimate resolution of the above guarantees is not expected to have a material effect on the Company’s consolidated earnings, financial position, or cash flows.</span></div>
CY2020 us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
313000000 USD
CY2019 us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
166000000 USD
CY2018 us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
61000000 USD
CY2020Q2 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
500000000 USD
CY2019Q2 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
500000000 USD
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7493000000 USD
CY2019Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7706000000 USD
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7717000000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5998000000 USD
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7384000000 USD
CY2018Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7481000000 USD
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7546000000 USD
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8146000000 USD
CY2019Q3 us-gaap Gross Profit
GrossProfit
5127000000 USD
CY2019Q4 us-gaap Gross Profit
GrossProfit
5312000000 USD
CY2020Q1 us-gaap Gross Profit
GrossProfit
5317000000 USD
CY2020Q2 us-gaap Gross Profit
GrossProfit
3734000000 USD
CY2018Q3 us-gaap Gross Profit
GrossProfit
5180000000 USD
CY2018Q4 us-gaap Gross Profit
GrossProfit
5278000000 USD
CY2019Q1 us-gaap Gross Profit
GrossProfit
5281000000 USD
CY2019Q2 us-gaap Gross Profit
GrossProfit
5663000000 USD
CY2019Q3 us-gaap Profit Loss
ProfitLoss
877000000 USD
CY2019Q4 us-gaap Profit Loss
ProfitLoss
1371000000 USD
CY2020Q1 us-gaap Profit Loss
ProfitLoss
1919000000 USD
CY2020Q2 us-gaap Profit Loss
ProfitLoss
640000000 USD
CY2018Q3 us-gaap Profit Loss
ProfitLoss
1077000000 USD
CY2018Q4 us-gaap Profit Loss
ProfitLoss
1120000000 USD
CY2019Q1 us-gaap Profit Loss
ProfitLoss
1271000000 USD
CY2019Q2 us-gaap Profit Loss
ProfitLoss
1182000000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
864000000 USD
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
1364000000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
1915000000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
646000000 USD
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
1075000000 USD
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
1115000000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
1269000000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
1172000000 USD
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.64
CY2019Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.02
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.43
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.48
CY2018Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.79
CY2018Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.83
CY2019Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.95
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.87
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.64
CY2019Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.01
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.42
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.48
CY2018Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.79
CY2018Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.82
CY2019Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.94
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.87
CY2020 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
4 segment
CY2020 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
4 segment
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
4055000000 USD
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
5197000000 USD
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
5675000000 USD
CY2020Q2 us-gaap Assets
Assets
90689000000 USD
CY2019Q2 us-gaap Assets
Assets
89694000000 USD
CY2020 us-gaap Depreciation
Depreciation
907000000 USD
CY2019 us-gaap Depreciation
Depreciation
895000000 USD
CY2018 us-gaap Depreciation
Depreciation
821000000 USD
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
28913000000 USD
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
30557000000 USD
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
29953000000 USD
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4828000000 USD
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4675000000 USD

Files In Submission

Name View Source Status
0001613103-20-000021-index-headers.html Edgar Link pending
0001613103-20-000021-index.html Edgar Link pending
0001613103-20-000021.txt Edgar Link pending
0001613103-20-000021-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
mdt-20200424.htm Edgar Link pending
mdt-20200424.xsd Edgar Link pending
mdt-20200424_cal.xml Edgar Link unprocessable
mdt-20200424_def.xml Edgar Link unprocessable
mdt-20200424_g1.jpg Edgar Link pending
mdt-20200424_g10.jpg Edgar Link pending
mdt-20200424_g11.jpg Edgar Link pending
mdt-20200424_g12.jpg Edgar Link pending
mdt-20200424_g13.jpg Edgar Link pending
mdt-20200424_g14.jpg Edgar Link pending
mdt-20200424_g15.jpg Edgar Link pending
mdt-20200424_g16.jpg Edgar Link pending
mdt-20200424_g17.jpg Edgar Link pending
mdt-20200424_g18.jpg Edgar Link pending
mdt-20200424_g19.jpg Edgar Link pending
mdt-20200424_g2.jpg Edgar Link pending
mdt-20200424_g20.jpg Edgar Link pending
mdt-20200424_g21.jpg Edgar Link pending
mdt-20200424_g22.jpg Edgar Link pending
mdt-20200424_g23.jpg Edgar Link pending
mdt-20200424_g24.jpg Edgar Link pending
mdt-20200424_g25.jpg Edgar Link pending
mdt-20200424_g26.jpg Edgar Link pending
mdt-20200424_g27.jpg Edgar Link pending
mdt-20200424_g28.jpg Edgar Link pending
mdt-20200424_g3.jpg Edgar Link pending
mdt-20200424_g4.jpg Edgar Link pending
mdt-20200424_g5.jpg Edgar Link pending
mdt-20200424_g6.jpg Edgar Link pending
mdt-20200424_g7.jpg Edgar Link pending
mdt-20200424_g8.jpg Edgar Link pending
mdt-20200424_g9.jpg Edgar Link pending
mdt-20200424_htm.xml Edgar Link completed
mdt-20200424_lab.xml Edgar Link unprocessable
mdt-20200424_pre.xml Edgar Link unprocessable
mdt-202010kxex21.htm Edgar Link pending
mdt-202010kxex24.htm Edgar Link pending
mdt-202010kxex311.htm Edgar Link pending
mdt-202010kxex312.htm Edgar Link pending
mdt-202010kxex321.htm Edgar Link pending
mdt-202010kxex322.htm Edgar Link pending
mdt202010k-ex1069.htm Edgar Link pending
mdt202010k-ex1070.htm Edgar Link pending
mdt202010k-ex22.htm Edgar Link pending
mdt202010k-ex23.htm Edgar Link pending
mdt202010k-ex424.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R100.htm Edgar Link pending
R101.htm Edgar Link pending
R102.htm Edgar Link pending
R103.htm Edgar Link pending
R104.htm Edgar Link pending
R105.htm Edgar Link pending
R106.htm Edgar Link pending
R107.htm Edgar Link pending
R108.htm Edgar Link pending
R109.htm Edgar Link pending
R11.htm Edgar Link pending
R110.htm Edgar Link pending
R111.htm Edgar Link pending
R112.htm Edgar Link pending
R113.htm Edgar Link pending
R114.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R89.htm Edgar Link pending
R9.htm Edgar Link pending
R90.htm Edgar Link pending
R91.htm Edgar Link pending
R92.htm Edgar Link pending
R93.htm Edgar Link pending
R94.htm Edgar Link pending
R95.htm Edgar Link pending
R96.htm Edgar Link pending
R97.htm Edgar Link pending
R98.htm Edgar Link pending
R99.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending